Clinical trial completion rates decline during COVID-19 pandemic
- Details
- Category: Research
Social distancing and lockdowns may have reduced the spread of COVID-19, but researchers from Penn State College of Medicine also report those actions may have affected clinical researchers' ability to finish trials. Study completion rates dropped worldwide between 13% and 23%, depending on the type of research sponsor and geographic location, between April and October 2020.
Study identifies possible COVID-19 drugs - including several that are FDA-approved
- Details
- Category: Research
A team led by scientists in the Perelman School of Medicine at the University of Pennsylvania has identified nine potential new COVID-19 treatments, including three that are already approved by the Food and Drug Administration (FDA) for treating other diseases.
COVID-19 convalescent plasma with greater antibody levels is safe and shows promise
- Details
- Category: Research
Convalescent plasma, the use of survivors' antibodies transfused into sick COVID-19 patients is safe and significantly improves clinical outcomes when using high levels of antibodies, according to a new publication by scientists at Hackensack Meridian Health, New Jersey's largest and most comprehensive health network.
Prioritizing who gets vaccinated for COVID-19 saves lives
- Details
- Category: Research
Waiting for your turn can be frustrating, especially when it comes to COVID-19 vaccinations. But prioritizing who receives the limited supply of vaccines available saves lives and reduces spread of infection, according to a study published in the journal PNAS from the University of California, Davis.
Undetected coronavirus variant was in at least 15 countries before its discovery
- Details
- Category: Research
A highly contagious SARS-CoV-2 variant was unknowingly spreading for months in the United States by October 2020, according to a new study from researchers with The University of Texas at Austin COVID-19 Modeling Consortium. Scientists first discovered it in early December in the United Kingdom, where the highly contagious and more lethal variant is thought to have originated.
COVID-19 survivors might need just one dose of two-part vaccine
- Details
- Category: Research
A single dose of the Pfizer-BioNTech vaccine for individuals who previously had COVID-19 generates an immunologic response similar to that of individuals receiving the two-dose recommended sequence, according to a Cedars-Sinai study published today by the journal Nature Medicine.
B.1.1.7 variant of COVID-19 spreading rapidly in United States
- Details
- Category: Research
The faster-spreading B.1.1.7 variant of SARS-CoV-2 first detected in the United Kingdom, the coronavirus that causes COVID-19, is quickly on its way to becoming the dominant variant of the virus in the United States, according to a study from scientists at Scripps Research and the COVID-19 test maker Helix.
More Pharma News ...
- Anti-inflammatory drug protects against lethal inflammation from COVID-19 in animal models
- Will COVID-19 vaccines need to be adapted regularly?
- Individual SARS-CoV-2 neutralising antibody immunity lasts from days to decades
- Hormone drugs may disarm COVID-19 spike protein and stop disease progression
- Targeting a new antibody supersite key to COVID immunity
- Leprosy drug holds promise as at-home treatment for COVID-19
- Variant B.1.1.7 of COVID-19 associated with a significantly higher mortality rate